【摘要】 近年来心力衰竭(心衰)药物治疗领域有诸多进展。神经内分泌抑制剂方面，血管紧张素受体脑啡肽酶抑制剂降低心衰事件和肾功能恶化风险；新型非甾体类盐皮质激素受体拮抗剂非奈利酮降低左室射血分数≥40%的心衰患者心衰恶化和心血管死亡风险。改善代谢的药物如钠葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在心衰中的获益不断被证实，特别是钠葡萄糖共转运蛋白2抑制剂已被用于全射血分数心衰。作用于细胞信号通路的药物如维立西呱改善射血分数减低心衰患者预后。中药芪苈强心胶囊临床研究取得重要进展，使射血分数减低心衰患者心血管死亡或心衰恶化风险降低。基于这些治疗进展，指南不断更新，遵循指南规范用药才能更好改善心衰患者预后。更多还原

【Abstract】 In recent years, there have been numerous advancements in the field of pharmacological treatment for heart failure(HF). Angiotensin receptor neprilysin inhibitors have been proven to reduce the risk of HF events and deterioration of renal function. The novel non-steroidal mineralocorticoid receptor antagonist, finerenone, lowers the risk of HF worsening and cardiovascular death in patients with left ventricular ejection fraction ≥ 40%. The benefits of metabolic-improving drugs such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in HF are constantly being confirmed. Particularly, sodium-glucose co-transporter 2 inhibitors have been utilized in HF with all ejection fractions. Vericiguat, a drug targeting cellular signaling pathways, has been shown to improve the prognosis of patients with HF with reduced ejection fraction. Notably, significant progress has been achieved in a randomized controlled study of the traditional Chinese medicine, Qiliqiangxin Capsule, which has been proven to reduce the risk of cardiovascular death or HF deterioration in patients with HF with reduced ejection fraction. Based on these therapeutic advancements, guidelines are constantly updated, and it is necessary to follow the guidelines for proper medication use to improve the prognosis of patients with HF.更多还原